C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 12.9 USD 3.2% Market Closed
Market Cap: 313m USD
Have any thoughts about
CVRx Inc?
Write Note

CVRx Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CVRx Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
C
CVRx Inc
NASDAQ:CVRX
Gross Profit
$33m
CAGR 3-Years
93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Gross Profit
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
8%
Boston Scientific Corp
NYSE:BSX
Gross Profit
$11B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Gross Profit
$14B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Gross Profit
$23B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Gross Profit
$5.3B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

CVRx Inc
Glance View

Market Cap
312.2m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
11.28 USD
Overvaluation 13%
Intrinsic Value
Price
C

See Also

What is CVRx Inc's Gross Profit?
Gross Profit
33m USD

Based on the financial report for Dec 31, 2023, CVRx Inc's Gross Profit amounts to 33m USD.

What is CVRx Inc's Gross Profit growth rate?
Gross Profit CAGR 3Y
93%

Over the last year, the Gross Profit growth was 89%. The average annual Gross Profit growth rates for CVRx Inc have been 93% over the past three years .

Back to Top